Avidity gets FDA Breakthrough Therapy designation for delpacibart etedesiran

Avidity Biosciences announced that the FDA has granted Breakthrough Therapy designation to delpacibart etedesiran, the company’s lead clinical development program, for the treatment of myotonic dystrophy type 1. Delpacibart etedesiran, abbreviated as del-desiran, is an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies.